Vilon research monograph — the Lys-Glu (KE) Khavinson immune/geroprotective dipeptide and its evidence base

Vilon is a synthetic dipeptide bioregulator from the Khavinson short-peptide family — L-lysyl-L-glutamic acid (Lys-Glu, often abbreviated "KE"). Developed within the cytomedine/cytogen program associated with the St. Petersburg Institute of Bioregulation and Gerontology, it sits in the immune/thymic wing of that family alongside Thymalin, Thymogen, and the tissue "bioregulators" elsewhere in this library, and is marketed for immune-support and geroprotective research. Unlike many vendor Khavinson peptides, Vilon has a genuinely defined sequence and a real — if regionally concentrated — experimental record spanning immune/thymus function, gene expression, tumor development, and animal lifespan. This monograph lays out the chemical identity, the mechanism hypothesis the family rests on, what the published research does and does not show, and the substantial evidence-quality caveats.

Chemical identity and structure.
Vilon is the dipeptide L-lysyl-L-glutamic acid (Lys-Glu; "KE"), molecular formula C₁₁H₂₁N₃O₅, molecular weight approximately 275 g/mol — one of the shortest members of the Khavinson bioregulator family (which ranges from di- to tetrapeptides). It was obtained by directed synthesis in the same research tradition that produced the thymic dipeptide Thymogen (Glu-Trp) and the pineal tetrapeptide Epithalon. It is supplied as a lyophilized white water-soluble powder. Because the family's activity is highly sequence- and chirality-dependent, the L-Lys-L-Glu configuration is part of the identity, and the controlling identity for any specific vial is the COA's stated sequence, not the brand name.

Mechanism of action.
The Khavinson framework hypothesises that ultrashort peptides enter cells, reach nuclear chromatin, and modulate gene expression in tissue-specific patterns determined by the peptide sequence — a regulatory/epigenetic model distinct from the receptor-pharmacology that dominates most peptide research. Vilon-specific published mechanistic work is consistent with that hypothesis: a DNA-microarray study reported that Vilon (and Epithalon) altered the expression of a set of genes in mouse heart tissue (Anisimov and colleagues, Bulletin of Experimental Biology and Medicine, 2002); Vilon has been reported to modify chromatin structure in cultured lymphocytes from elderly donors (75–88 years), consistent with reactivation of repressed genes (Lezhava et al., Georgian Medical News, 2006, in vitro human cells); to stimulate argyrophilic proteins of the nucleolar organiser regions and push thymocytes toward proliferating blasts (Raikhlin et al., Bull. Exp. Biol. Med., 2004, in vitro human thymocytes/epitheliocytes); and to raise the CD5 differentiation marker and drive T-cell-precursor differentiation toward CD4⁺ helper cells (Sevost'ianova et al., Bull. Exp. Biol. Med., 2013, thymus cell cultures). These findings are consistent with a low-dose gene-regulatory action in immune tissue, but the mechanism remains hypothesis-level relative to receptor-agonist standards, and the strongest data still comes from within the Khavinson research network rather than independent replication.

Research applications and the evidence base.
Vilon's marketed theme is immune/thymus support and geroprotection, and there is a real preclinical record behind it — but it is overwhelmingly animal-model and in-vitro, and concentrated in one research tradition. On the immune side, in aged and immunocompromised animal and organ-culture models Vilon has been reported to reduce radiation-induced apoptosis of spleen lymphocytes (Khavinson & Kvetnoi, 2000), limit radiation-induced premature aging of thymus and spleen (Kniaz'kin & Poliakova, 2002), normalise lymphocyte counts and lower morbidity in immunosuppressed rats (Ivanov et al., 2005), and stimulate regeneration and cell proliferation in young and aged rat spleen organotypic cultures (Bykov, Chalisova, and colleagues). On the geroprotection/oncology side, in female CBA mice Vilon increased physical endurance and mean life span and reduced neoplasm development (Khavinson, Anisimov & Zavarzina, Bull. Exp. Biol. Med., 2000), and it inhibited chemically induced urinary-bladder carcinogenesis in rats (N-butyl-N-(4-hydroxybutyl)nitrosamine model: tumours in 56% of Vilon-treated animals versus 75.5% of controls, with roughly a two-fold reduction in preneoplastic/early-neoplastic changes — Pliss, Mel'nikov, Malinin & Khavinson, Bull. Exp. Biol. Med., 2001). These are specific, model-bound results and should not be read as a general anticancer effect — they come from particular induced- and spontaneous-tumour models, not from broad or human oncology data. Human data are limited and low-certainty: beyond the animal and in-vitro record, the human evidence consists of a small number of regional (largely Russian) clinical reports from within the same research tradition — for instance, reported effects on hemostasis and a reduced insulin requirement in elderly type-1 diabetics (Kuznik et al., 2006–2007) and reported improvements in two-year survival and quality of life in elderly colorectal-cancer patients (Yas'kevich et al., 2005). These should be read as illustrative of that limited regional record, not as established findings: they are small, not independently replicated outside the originating tradition, and have not been reproduced in Western-standard trials. There are no completed Western Phase III human clinical trials of Vilon, and it is not registered or approved for human use in any major Western jurisdiction; the record overall is dominated by the Khavinson research tradition with limited independent replication.

Research context.
Vilon is the Lys-Glu member of the Khavinson bioregulator family and sits closest to the immune/thymic peptides: the dipeptide Thymogen (Glu-Trp) and the parent thymus preparation Thymalin (a multi-peptide extract, not a single molecule — a distinction to keep when comparing them). It is also routinely discussed alongside Epithalon (pineal/longevity research) and the tissue-targeted bioregulators (Cortagen, Prostamax, Vesugen, and others in this library), which share the discovery framework and the gene-regulation hypothesis but address different tissues. A caution that runs through the whole family: activity is strongly sequence- and chirality-dependent — Thymogen's mirror-image isomer (Thymodepressin) has the opposite, immunosuppressive effect — so precise identity is not a formality here.

Storage and handling.
Lyophilized Vilon should be kept refrigerated (2–8 °C) and protected from light. The peptide tolerates refrigerator-temperature storage reasonably well but does not tolerate repeated freeze-thaw cycles.

Quality and COA considerations.
A meaningful COA for a vendor-grade Vilon vial should confirm identity by mass spectrometry against the expected molecular weight (~275 g/mol) and, most importantly, report the amino-acid sequence (Lys-Glu) — brand-name-only labelling is insufficient, and mislabelling between the short Khavinson peptides is a known quality issue in this market. Because activity depends on chirality, the L-Lys-L-Glu configuration is part of what a COA should establish. Purity by HPLC (≥98% benchmark) and sterility/endotoxin testing for any vial intended for injection-model use should also be reported.

*Research-use note: This monograph is an educational summary of the published research literature on Vilon (Lys-Glu). The evidence base is predominantly animal-model and in-vitro and is concentrated within the Khavinson research tradition; human data are limited to small regional reports, the compound has not been evaluated in completed Western Phase III human clinical trials, and it is not approved for human use in any major jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.